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Abstract: Early results of hand and face transplants and other grafts such as those of uterus, penis,
trachea, larynx, or abdominal wall have confirmed the potential for vascularized composite allotransplan-
tation (VCA) to restore appearance, anatomy, function, independence, and social integration in patients
suffering from devastating tissue deficits untreatable by conventional treatment options. Despite such
promise, these novel and complex procedures face challenges and controversies that remain open to discus-
sion and debate. Indeed, many barriers to clinical advancement and negative stakeholder perceptions still
exist. The bioethical challenges surrounding VCA include but are not limited to justice and vulnerability
of subjects, and their experiences with risks, benefits and outcomes, provider economy of fame, public
awareness and attitudes toward transplantation, and policy and regulatory issues shaping progress of the
field. The First International Workshop on Bioethical Challenges in Reconstructive Transplantation was
organized by the Brocher Foundation in Hermance, Switzerland. VCA professionals representing teams
from across the world examined bioethical issues in VCA related to standards for safety, efficacy, feasibil-
ity, privacy, confidentiality, and equitability. Key discussion topics from the workshop were included in a
survey questionnaire implemented across VCA professionals attending the 13th Congress of International
Society of VCA held in Salzburg, Austria. The insights from the Brocher workshop and International
Society of VCA survey as presented here could help inform the future development of clinical practice and
policy strategies in VCA to ensure value, accessibility, and acceptance of these procedures by potential
donors, potential or actual recipients and their families, and providers and payers.
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Working Group
Gerard Magill, PhD,1 James Benedict, PhD,1 Jan A. Plock, MD,2,3 Tanja Krones, PhD,4  
and Vijay S. Gorantla, MD, PhD, FRCS5; the Brocher Working Group on VCA
INTRODUCTION
The technical, immunological, and functional feasibility 
of vascularized composite allotransplantation (VCA) as 
a promising reconstructive/restorative option has been 
established for procedures such as hand or face trans-
plantation.1 Despite over 250 VCA procedures across 
the world to date, and significant federal funding for 
research in improving safety, efficacy, and applicability 
of VCA, much remains to be understood in the areas of 
immunosuppressive risk, rigorous adherence to medica-
tions or rehabilitation, and psychosocial issues.2 Broader 
impact and clinical feasibility for VCA will be difficult to 
realize if bioethical concerns involving key stakeholders 
such as the public, patients, providers, and payers remain 
unresolved.3
The First International Workshop on Bioethical 
Challenges in Reconstructive Transplantation was organ-
ized at the Brocher Foundation in Hermance, Switzerland, 
on May 9–12, 2017. Ethical concerns about VCA had 
received attention in the peer literature and media over the 
past 2 decades. However, there was no formal discussion 
of contemporaneous or emerging bioethical challenges in 
VCA under the auspices of either the American Society for 
Reconstructive Transplantation or International Society of 
VCA (ISVCA). With over 250 transplants to date, many 
VCA experts agreed that the maturity of the field and 
long-term insights necessitated a concentrated focus on 
Meeting Report
Abstract. Early results of hand and face transplants and other grafts such as those of uterus, penis, trachea, larynx, or 
abdominal wall have confirmed the potential for vascularized composite allotransplantation (VCA) to restore appearance, 
anatomy, function, independence, and social integration in patients suffering from devastating tissue deficits untreatable by 
conventional treatment options. Despite such promise, these novel and complex procedures face challenges and contro-
versies that remain open to discussion and debate. Indeed, many barriers to clinical advancement and negative stakeholder 
perceptions still exist. The bioethical challenges surrounding VCA include but are not limited to justice and vulnerability of 
subjects, and their experiences with risks, benefits and outcomes, provider economy of fame, public awareness and attitudes 
toward transplantation, and policy and regulatory issues shaping progress of the field. The First International Workshop on 
Bioethical Challenges in Reconstructive Transplantation was organized by the Brocher Foundation in Hermance, Switzerland. 
VCA professionals representing teams from across the world examined bioethical issues in VCA related to standards for 
safety, efficacy, feasibility, privacy, confidentiality, and equitability. Key discussion topics from the workshop were included in a 
survey questionnaire implemented across VCA professionals attending the 13th Congress of International Society of VCA held 
in Salzburg, Austria. The insights from the Brocher workshop and International Society of VCA survey as presented here could 
help inform the future development of clinical practice and policy strategies in VCA to ensure value, accessibility, and accept-
ance of these procedures by potential donors, potential or actual recipients and their families, and providers and payers.
(Transplantation 2019;103:1746–1751)
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
<zdoi;10.1097/TP.0000000000002606>
© 2019 Wolters Kluwer Magill et al 1747
the bioethical implications. This was the impetus for the 
Brocher workshop, which was the first formal discussion 
of the bioethical dilemmas, challenges, and controver-
sies that beset the field of VCA. The primary goals of the 
Brocher workshop were to facilitate an in-depth consid-
eration and delineation of the bioethical issues pertinent to 
VCA research and practice and make recommendations to 
promote ethical conduct of VCA procedures.
This first formal international exploration of bioethics 
in VCA brought together from across the world pioneers 
and experts in clinical VCA, bioethicists, psychologists, 
and organ procurement professionals, as well as opinion 
leaders in the humanities, health economics, law, and pol-
icy to clarify and explore the spectrum of ethical issues 
raised by VCA. We present the most important themes and 
topics discussed at the Brocher workshop and key recom-
mendations made by the expert panels.
Candidate Vulnerabilities
The participants at Brocher accept the notion that VCA 
candidates may be regarded as especially vulnerable. The 
special vulnerability of VCA candidates is underscored 
by their willingness to endure significant treatment and 
rehabilitation burdens and accept substantial risks for 
nonlife-saving VCA to participate in research protocols 
with unknown long-term outcomes. Given the vulner-
ability of candidates, those at Brocher emphasized that 
special protections must be in place to ensure that they 
are fully informed of the risks and benefits of these pro-
cedures.4 Among the ideas put forward were improved 
patient decision aids, such as exposure to a range of peers 
including those who had decided against VCA and those 
who had successfully undergone the treatment, and the 
use of an independent patient advocate to accompany and 
advise the patient in interactions with the medical team. 
Given that those most eager to have VCA may also be the 
most desperate and least able to cope with the stringent 
demands and inevitable setbacks in treatment, improve-
ments in psychosocial screening were also seen as a means 
of optimizing patient selection compatible with the best 
predicted graft outcomes.5
Patient Experiences
Patient experience was recognized as an underuti-
lized resource for quality improvement in VCA. Further 
research was recommended in the challenges and bur-
dens experienced and perceived by patients and what they 
might change about the process. This could be particularly 
valuable for addressing patients’ problems with adherence 
to immunosuppression, physiotherapy, and follow-up care 
management. The collection of data on patient experiences 
could also assist in developing definitions of what consti-
tutes success in VCA and improving informed consent. 
Some participants noted that body image matters more 
to some recipients, while others place a higher priority on 
function.6
Justice and Respect for Dignity
The participants discussed whether it was just to dedi-
cate precious and limited institutional and public resources 
to support emerging or unproven VCA procedures despite 
their potential benefits to select individuals, when those 
same resources might meet more impactful needs of the 
population or preventative health.7 There was an agree-
ment that the ethical justification of VCA requires that 
the issue of justice, or fairness in the allocation of scarce 
resources, be taken seriously. The participants recom-
mended that essential steps in determining need for VCA as 
a treatment in eligible subjects were to consider the impact 
of VCA on the treatable defect  for the candidate’s sense 
of dignity and thoroughly evaluate alternative options for 
VCA.8,9 In light of the major burdens and risks, it was 
argued that while it would be unethical to pursue VCA 
without a thorough exploration of alternatives, it remains 
plausible that for some people, the alternatives may be 
inadequate and VCA may be the only option. The Brocher 
group affirmed that respect for dignity must also extend 
to donors and donor families with due planning for pre-
serving donor body integrity as much as feasible following 
VCA procurement.10
Privacy Concerns
The ethical duty to protect the privacy of patients and 
donors is beyond dispute, but the challenges involved in 
doing so in VCA are great. Participants at Brocher acknowl-
edged the challenges and inherent conflict between physi-
cian desire or institutional eagerness for publicity and the 
recipient or donor right to privacy. It was agreed that both 
recipients and donor families should be advised that the 
identity of recipient and donor is likely to become public, 
despite the most comprehensive policies and procedures to 
maximize privacy.11
Procurement, Allocation, and Policy Issues
Unlike standardized procurement and allocation sys-
tems for solid organs (heart, lung, liver, kidney, and pan-
creas), VCAs continue to be procured and allocated on an 
ad hoc basis.12-14 Concern was expressed at Brocher for 
how requests for VCA donations might negatively impact 
willingness to donate life-saving organs. Publicity and pub-
lic education about the possible donation of faces, upper 
extremities, penises, and uteri must be carefully managed 
so as not to discourage donor registration in explicit con-
sent countries or cause individuals in presumed consent 
countries to opt out.15 Additional concern was expressed 
about the importance of designing policy and methods 
of procurement which honor the dignity of donors and 
their next of kin. Questions were raised about whether 
presumed consent or first-person authorization should be 
regarded as sufficient or whether next-of-kin assent should 
also be required. The group also considered whether 
potential VCA donation choices (face, upper extremities, 
penis, uterus, etc) ought to be explicitly listed on driver 
license consents and authorized by potential donors.16 It 
was acknowledged that transparency is vital and much 
work is needed in this area.
Subject Selection
Subject selection has received a great deal of attention in 
the literature, primarily because nonadherence to immu-
nosuppression and physiotherapy has played a large role 
in poor outcomes.6 Subject selection is an ethical concern 
both on the grounds of justice (fairness) and the grounds of 
beneficence and nonmaleficence. It would clearly be uneth-
ical to transplant a patient without due diligence in selec-
tion to assure an excellent chance of success. Discussion 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
1748 Transplantation  ■  September 2019  ■ Volume 103  ■  Number 9 www.transplantjournal.com
on this topic at Brocher on standards for exclusion focused 
on the need for the identification or development of more 
reliable psychosocial screening instruments. It was recom-
mended that programs must be open to the use of psycho-
therapy to help resolve conditions that would otherwise 
exclude candidates.
Risk-benefit Issues
Prominent in the discussion of risk-benefit analysis 
was the recognition of the substantial burdens placed on 
recipients and their loved ones. In many cases, wages or 
employment may be lost due to protracted rehabilitation 
or demands on recipient caregivers.17 The Brocher experts 
pointed out that travel to and from the transplant center 
for screening and postsurgical follow-up, careful following 
of the medication regimen, daily self-monitoring for signs 
of rejection, and rigorous long-term physical therapy were 
some of the foreseeable burdens for patients. They felt that 
alongside these burdens, the risks of rejection, graft loss, 
opportunistic infections, the development of new meta-
bolic diseases, and even death create the need for a very 
substantial and highly justifiable benefit to support a trans-
plant whose goal is not to save the life or extend the life 
span of the recipient. This, in turn, raises questions about 
what degree of injury or functional impairment should 
be regarded as necessary in a recipient to be considered 
for VCA. It was noted at Brocher that the definitions of 
success and failure in different VCA were complicated or 
controversial and challenge consensus. They demanded an 
urgent discussion of these criteria among VCA teams with 
inclusion of physician, patient, and caregiver input.
Program Standards
Given the risks and burdens imposed on the patients 
and the great cost to society involved in VCA, the Brocher 
participants noted that the principles of nonmaleficence 
and justice must be implicated in the call for high program 
standards.18 However, not all programs have adhered to 
high standards, leading to exceptionally poor results in 
some programs. There was uniform agreement among par-
ticipants that program quality is essential for the ethical 
justification of VCA and international program standards 
must be established and enforced by every center perform-
ing VCA. The Brocher group discussed the rapid increase 
in the number of centers seeking program approval and 
the potential for a dilution of quality, as experience at any 
given center may be limited by scarce resources, a small 
pool of appropriate candidates, or other factors. Limiting 
the number of centers to those institutions with established 
expertise in VCA that was supplemented by high-volume, 
solid organ transplant program support could help in 
improving the quality of outcomes. It was noted that pres-
sure can be high in some academic centers to justify enroll-
ments for federally funded grants to meet milestones or 
merely to achieve firsts in VCA with teams or institutions 
rushing the process.
Informed Consent
The discussion at Brocher on informed consent 
focused on the following major concerns: the first was 
about the information owed to candidates on VCA, 
how it should be delivered, and how understanding 
should be assessed.19 The second concern was related to 
the burdens, commitments, and demands of VCA that 
include adherence with long-term immunosuppression 
and follow-up recommendations and often engage-
ment in years of physiotherapy for optimal results.20 It 
was recommended that new information on outcomes 
(especially risks/complications) be shared with patients 
verbally and in writing and integrated into the consent. 
Such ongoing updates to the consent of patients could 
improve compliance with transplant recommendations 
and enable informed patient participation in their own 
care management. The Brocher group recommended the 
use of the informed consent as a dynamic covenant to 
promote a stronger sense of postsurgical accountability 
in patients and caregivers.21
Physician and Program Responsibility and 
Accountability for Outcomes, Public Trust, and the 
Perception of VCA
The novelty or relative rarity of VCA procedures and 
their transformational impact on patients with devastat-
ing tissue defects has contributed to their sensationalism 
in modern media.22 Brocher participants uniformly con-
curred that sensationalistic portrayals fail to fairly repre-
sent the burdens, risks, and disappointments even in the 
cases with the best outcomes.23,24 Equally important, the 
Brocher group strongly urged providers to refrain from the 
seduction of economy of fame in VCA, as it could irrepa-
rably damage public trust.25 In this regard, meeting par-
ticipants highlighted the ethical obligation for timely and 
transparent disclosure of successes and complications or 
failures by teams in the peer literature. Transparency facili-
tates the development of public trust, which is critical for 
future funding and to encourage donation. They expressed 
serious concern that a few programs in the field have not 
been faithful in publishing their results, obscuring the 
true picture of setbacks or advancements. Timely report-
ing can help identify best practices and prevent harm to 
other transplant recipients. The Brocher participants noted 
that treatment teams must honor the contributions of the 
recipient to the research enterprise as it is the recipients 
who shoulder the greatest risks and burdens, even as they 
hope for benefit.
Patient Responsibility and Accountability
In many ways, being a VCA recipient is akin to hav-
ing a chronic progressive illness. The Brocher group noted 
that graft survival and function, as well as the quality of 
life, depended a great deal on the consistent, active partici-
pation of the recipient in his or her own care. That par-
ticipation, in turn, depends, in part, on the quality of the 
relationships the recipient has with others, including the 
medical team.
Discussion focused on what it was reasonable to expect 
of recipients, how best to communicate effectively what is 
expected, and when and how to hold recipients account-
able for their actions that impact transplant outcomes. It 
was felt that further research was needed to understand 
why recipients sometimes fell short of what was expected 
and what interventions were most effective in such situa-
tions. In light of these aspects of VCA, the Brocher group 
recommended close attention to the therapeutic alliance 
over the whole course of the treatment. The foundation 
for the alliance may be established in the informed consent 
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phase and reinforced with ongoing disclosure of new infor-
mation to patients with emphasis on open communication 
and mutual accountability.
Exit Strategies
Finally, in light of the perpetual possibility of graft loss 
and high probability of eventual graft loss, it was agreed 
FIGURE 1. Survey results from the Bioethics Symposium, International Society of Vascularized Composite Allotransplantation 2017, 
Salzburg, Austria. The survey results are shown with average response and total response numbers based on a Likert-type, 1 to 5 
response scale, with 1 indicating strongly disagree, 2 indicating disagree, 3 indicating neutral, 4 indicating agree, and 5 indicating 
strongly agree (see key). The total number of survey participants was 60. VCA, vascularized composite allotransplantation.
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that there is an ethical duty to thoroughly consider all 
known exit or life-boat strategies before transplantation. 
The Brocher group agreed that exit strategies are complex 
and could be unique to particular VCA, with face trans-
plants having the greatest risk profile. In the event that a 
second transplant is not feasible and if there is not a suffi-
cient amount of tissue available for autologous reconstruc-
tion, the loss of a face graft could be fatal.26 It is, therefore, 
ethically imperative to attempt to determine the likely 
alternative options to VCA and end outcomes of VCA and 
discuss these as part of the consent process.
Following the Brocher workshop, the most important 
bioethical questions that were discussed at the meeting 
were formulated into a survey questionnaire, which was 
implemented across VCA professionals attending the 13th 
Congress of ISVCA held in Salzburg, Austria in October 
2017.27
The results of the ISVCA meeting survey are summarized 
in Figure 1. These 13 questions spanned the some impor-
tant bioethical dilemmas and challenges surrounding these 
procedures. The surveyed pool of 60 participants repre-
sented key stakeholders in VCA who were in attendance at 
the ISVCA meeting. These included an international group 
of VCA surgeons, transplant physicians, immunologists, 
physical therapists, psychologists, bioethicists, transplant 
social workers, and organ procurement professionals. The 
interpretation of the anonymous survey shed valuable and 
interesting insights into the perceptions and attitudes as 
well as biases among the participants in their responses to 
key bioethical questions in VCA (Table 1).
Taken together, the purpose of the Brocher workshop 
and ISVCA survey was not to seek consensus but obtain 
critical early insights into the state of bioethics in VCA to 
help direct meaningful debate and recommendations for 
improvement. The common themes that emerged from 
both the workshop and survey are the following:
There is a need for prompt, rational, effective, objective, rigor-
ous, and deliberate evaluation of the bioethical impact and 
implications of existing and novel therapeutic options for 
individual VCA procedures by all programs.
Providers must bear the ethical responsibility to maximize 
benefits and optimize outcomes of VCA and facilitate vali-
dation of safety, efficacy, and feasibility of protocols across 
participants from different demographic, ethnic, and etio-
pathologic groups.
VCA programs must ensure open data sharing and transpar-
ent, timely disclosure of outcomes to peers and public.
Programs must collaborate more and agree on study stand-
ards, uniform assessments, or data points and pooling of 
data or comparison of results among centers (that indi-
vidually lack necessary sample size or randomization). This 
could increase generalizability of outcomes after VCA and 
may indeed be the best means of increasing the quality of 
TABLE 1. 
Interpretation of bioethics survey response
Question 1 The ratio of respondents who agreed or strongly agreed that many programs are slow, partial, and biased in reporting 
outcomes to those respondents who disagreed or strongly disagreed was almost 3:1.
Question 2 The ratio of respondents who agreed or strongly agreed that it is ethically unacceptable to not disclose graft losses to 
those respondents who disagreed or disagreed strongly was >4:1.
Question 3 The ratio of those who agreed that full data sharing must be a program standard to those who disagreed was 7:1.
Question 4 The ratio of those registering agreement or strong agreement with the statement that lack of transparency puts the 
entire field at risk to the number registering disagreement or strong disagreement was almost 5:1.
Question 5 The ratio of those supporting living-related uterine transplants to those opposing it was >2:1. However, almost one-
third of respondents were neutral.
Question 6 While respondents leaned toward halting combination VCA, only slightly more than half (54%) either agreed or strongly 
concurred with this recommendation.
Question 7 The ratio of those who agreed that it is ethical to perform pediatric VCA on the basis of proxy (parental) consent to 
those who disagreed was >2:1. However, nearly one-fourth of respondents were neutral on this issue.
Question 8 The ratio of respondents who felt that lower limb transplantation did not offer benefit vs risk over prostheses for 
above-the-knee amputation compared with those who believe it did was almost 2:1.
Question 9 Respondents leaned toward agreement that there are no ethical guidelines regarding responsibility for follow-up, but 
almost a third of respondents were neutral.
Question 10 The ratio of respondents who did not seem to feel indications and selection standards for hand and face were clearly 
established with consensus, to those who considered them as well established was with a >2:1 ratio. However, 
more than one-fourth of respondents took a neutral stance.
Question 11 Middle positions (agree/neutral/disagree) predominated and were balanced around the question of the ability of 
current psychosocial screening to identify excellent candidates. We are clearly far from consensus on this matter.
Question 12 The respondents leaned heavily (38:7) in the direction of agreement or strong agreement in response to the statement 
that the ethical justification of VCA requires greater consensus on definitions of success or failure in the field.
Question 13 On the question of whether it is ethical to offer VCA in which death is the only exit strategy, middle positions (agree/
neutral/disagree) predominated and were roughly balanced. Stronger opinions (strongly agree or strongly disagree) 
were less frequent than in many other survey questions.
Questions 1 to 4 addressed the importance of transparency and reporting. The results show strong support for improvements in this area. Questions 5 to 8 and 13 addressed benefit-risk. Respondents 
were quite divided on these issues. Questions 9 to 12 dealt with program standards. The diversity of opinion in the field was reflected in the responses to these questions, with the only solid directional 
preference coming in response to the suggestion that there was a need for greater consensus on success and failure definitions.
VCA, vascularized composite allotransplantation.
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evidence for clinical decision making, provide objective 
cost analysis,28 and inform health policy for approval and 
adoption of a given VCA as a standard of care, safe, effec-
tive, and ethical therapeutic option.29,30 
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